Cellyan Biotechnology Co., Ltd has successfully regained compliance with the Nasdaq Stock Market's minimum bid price requirement. This achievement comes after the company faced challenges with its stock price, which had fallen below the necessary threshold. The compliance reinstatement is crucial for Cellyan as it allows the company to maintain its listing on the Nasdaq Capital Market, ensuring continued access to capital and investor confidence.
On November 13, 2026, Cellyan received a notification from the Listing Qualifications Department of Nasdaq confirming that its Class A ordinary shares had a closing bid price at or above $1.00 for 14 consecutive business days, from October 26 through November 12, 2026. This compliance with Nasdaq Listing Rule 5550(a)(2) marks the closure of the matter regarding the minimum bid price requirement.
Background
Cellyan Biotechnology Co., Ltd, incorporated in the Cayman Islands, operates in the wholesale-drugs industry (SIC 5122). The company, which trades on the Nasdaq under the ticker HKPD, specializes in over-the-counter pharmaceutical cross-border e-commerce supply chain services. Cellyan's recent filings include a series of 6-K forms, with the latest filed on November 16, 2026, detailing its compliance status.
What the Filing Says
The recent filing indicates that Cellyan has regained compliance with Nasdaq's minimum bid price requirement, stating, "the Company has regained compliance with the Minimum Bid Price Requirement, and the matter was closed." This marks a significant turnaround for the company after it was previously notified of non-compliance in January 2026.
Impact
This development is likely to affect various stakeholders, including investors and the company's management. Investors can feel more secure about their holdings, and the management team can focus on strategic growth without the pressure of potential delisting. The reinstatement of compliance also reflects positively on the broader wholesale-drugs industry as companies navigate similar challenges in maintaining their market positions.
What's Next
The filing does not say what happens next. However, Cellyan is expected to continue its operations and focus on enhancing its service offerings in the competitive pharmaceutical e-commerce space.
Read Next
Dominion Energy announces $1.2 billion senior notes issuance
Lakefront Biotherapeutics Launches €50 Million Share Buyback
Coca-Cola Europacific Partners Announces Share Buyback Details
Zenta Group announces $6.47 million at-the-market offering
MapLight Therapeutics Enters $100 Million Sales Agreement
Cyabra, Inc. Secures $15.6 Million in Private Placement










